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Initial Lymph Node Dissection Increases Cure Rates
in Patients with Medullary Thyroid Cancer
David Yü Greenblatt, Diane Elson,1 Eberhard Mack and Herbert Chen, Departments of Surgery and 
1Medicine, University of Wisconsin, Madison, Wisconsin, USA.
OBJECTIVE: Medullary thyroid carcinoma (MTC) is the third most common type of thyroid cancer.
MTC spreads early to local lymph nodes, and most endocrine surgeons recommend total thyroidectomy
with central lymph node dissection (CLND) as the minimum initial operation. We reviewed our experience
to determine if the initial operation influences clinical outcomes.
METHODS: Twenty-two patients with sporadic or inherited MTC who received surgery at one academic
centre between 1994 and 2004 were identified. Clinical, operative, and pathology findings were reviewed.
RESULTS: Ten patients had prophylactic thyroidectomy for hereditary MTC, while 12 patients under-
went therapeutic operations for sporadic MTC. The average age of the prophylactic group was 11 ± 3, and
43 ± 6 years for the therapeutic group. All patients in the prophylactic group received thyroidectomy without
neck dissection. No patient in the prophylactic group had residual disease or required re-operation. In the
therapeutic surgery group, three patients were treated with thyroidectomy plus CLND, and nine patients
received thyroidectomy alone. The CLND group had a significantly higher cure rate as demonstrated by 
a lower incidence of residual disease (0% vs. 89%, p = 0.018), and re-operations (0% vs. 78%, p = 0.045).
CONCLUSION: Initial CLND for MTC increases cure rates by reducing residual disease and re-operations.
[Asian J Surg 2007;30(2):108–12]
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Introduction
Medullary thyroid carcinoma (MTC) is the third most
common type of thyroid cancer, accounting for approxi-
mately 2–5% of all cancers of the thyroid gland.1 The nat-
ural history of MTC is significant for early metastasis to
the central neck compartment and other local and
regional lymph nodes. In advanced cases, MTC can invade
local structures such as the trachea and jugular vein, and
metastasize to distant organs such as the liver, lungs, and
bone.2
Approximately 75% of MTC cases are sporadic, and 25%
are hereditary. Sporadic MTC usually presents as a unifo-
cal clonal population of tumour cells, while the heritable
forms are typically multifocal and bilateral. Hereditary
MTC has an earlier onset and, in MEN2B, a more aggres-
sive course. Hereditary MTC is caused by mutations in the
RET proto-oncogene, located on chromosome 10.
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Total thyroidectomy is the accepted prophylactic ther-
apy for patients with hereditary MTC. The timing of sur-
gery depends on the patient’s hereditary MTC syndrome.
With an understanding of the genotype–phenotype corre-
lations in hereditary MTC, the timing and extent of sur-
gery can be tailored to the patient’s particular RET codon
mutation.
Some controversy exists regarding the optimal initial
treatment for sporadic MTC. Historically, many general
surgeons performed total thyroidectomy alone for the
disease. With the understanding that MTC often has
already spread to local lymph nodes at the time of pre-
sentation, most endocrine surgeons now advocate thy-
roidectomy and central lymph node dissection (CLND) as
the minimum initial operation. Some centres routinely
add modified radical neck dissection when the primary
tumour is palpable or the lymph nodes are involved.
Given this background, we reviewed our experience 
in treating MTC to determine whether or not CLND
influences cure rates in patients receiving initial surgery
for MTC.
Patients and methods
A review of the University of Wisconsin Hospital opera-
tive database identified 22 patients with sporadic or 
inherited MTC who received initial thyroid surgery over 
a 10-year period. Clinical, operative, and pathology findings
were reviewed.
Statistical analysis was performed by analysis of vari-
ance, and disease-free survival curves were prepared using
the Kaplan–Meier method (SPSS 10.0; SPSS Inc., Chicago,
IL, USA). Cure was defined as the absence of clinical, radio-
graphic or biochemical (i.e. elevated basal serum calci-
tonin) evidence of MTC at the time of last follow-up.
Significance was defined as a p value of < 0.05.
Results
Of the study population of 22 patients, 10 patients
received prophylactic surgery for hereditary MTC, and 12
had therapeutic surgery for a thyroid nodule diagnosed
preoperatively as MTC. Only patients receiving their first
thyroid operation were included. The average age of the
prophylactic surgery group was 11 ± 3 years, compared to
43 ± 6 years for the therapeutic group (p < 0.001). Just over
half of the patients in each group were female (Table 1).
Prophylactic surgery for hereditary MTC
Ten patients received prophylactic thyroid resection
because of hereditary MTC. Importantly, no prophylactic
CLNDs were done. Two patients had foci of MTC in their
resected thyroid specimens. The tumours were small,
measuring 3 mm and 4 mm, respectively. No patient in the
prophylactic surgery group had residual disease or required
a further thyroid operation.
Therapeutic surgery for MTC
Twelve patients had initial surgery for a thyroid nodule
diagnosed as MTC. Re-operative cases were not con-
sidered in this study. Nine patients received total thy-
roidectomy alone, and three received thyroidectomy plus
CLND. The Thyroidectomy Alone Group on average was
younger, more predominantly female, and had slightly
smaller tumours than the CLND Group. These differ-
ences, however, were not statistically significant (Table 2).
The average follow-up time for the Thyroidectomy Alone
Group was 85 ± 13 months while the CLND Group had
an average follow-up time of 71 ± 34 months. However,
this difference was also not statistically significant
(p = 0.65).
Interestingly, more extensive surgery was not associ-
ated with an increase in perioperative complications. In
fact, the converse was true: there were more complications
in the Thyroidectomy Alone Group than the CLND Group.
The three complications in the Thyroidectomy Alone
Group included unilateral vocal cord paralysis, pneumonia
and transient hypocalcaemia. After an average follow-up
time of 80 months, one patient in the Thyroidectomy
Alone Group had died from MTC. There were no com-
plications or deaths in the CLND Group. These differ-
ences in morbidity and mortality, however, did not reach
statistical significance.
Comparing treatment outcomes, the Thyroidectomy
Alone Group had a significantly higher rate of MTC recur-
rence than the CLND Group. In the Thyroidectomy Alone
Group, eight of nine patients had recurrent MTC, and
■ LYMPHADENECTOMY INCREASES CURE RATES IN MTC ■
ASIAN JOURNAL OF SURGERY VOL 30 • NO 2 • APRIL 2007 109
Table 1. Patient characteristics
Group n Age (yr) Female (%)
Prophylactic 10 11 ± 3 55
Therapeutic 12 43 ± 6 58
p < 0.001 NS
NS = not significant.
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seven went on to have additional surgery. One patient
who had recurrent disease refused further surgical treat-
ment. In contrast, none of the patients who received
CLND had disease recurrence, and no patient required 
re-operation (Table 3). The difference in disease-free 
survival between the two groups is illustrated in the
Figure, which shows divergent Kaplan–Meier survival
curves.
The cure rate among patients who received CLND was
100%, compared to only 11% in the Thyroidectomy Alone
Group. This difference was statistically significant. We
defined cure as the absence of clinical, radiographic or
biochemical evidence of MTC at the time of last follow-up
(Table 3).
Discussion
MTC, which arises from calcitonin-secreting parafollicular
cells of the thyroid gland, accounts for 2–5% of all cases of
thyroid cancer in the United States.1 Average 5-year survival
for MTC (83%) is lower than for papillary and follicular
thyroid cancer (90–94%).3,4 The natural history of MTC is
significant for early metastasis to local and regional lymph
nodes, and decreased survival in MTC can be accounted
for in part by a high proportion of late-stage diagnoses.3–6
Unlike papillary and follicular carcinomas, MTC does not
concentrate radioiodine, eliminating this as an adjuvant
treatment modality. MTC also does not generally respond
to external beam radiation.7 For these reasons, complete
surgical resection currently represents the only chance for
cure in patients with MTC.8
MTC occurs in sporadic and familial forms. In a Swedish
population-based study, hereditary MTC accounted for
26% of all MTC cases.9 Among patients with MTC treated
at some tertiary referral centres, the proportion with
hereditary MTC may be much higher, e.g. 44% in a case
series from the University of California, San Francisco.10
In recent years, genotype–phenotype correlations have
been used to stratify risk in hereditary MTC. Decisions
regarding the timing and extent of prophylactic surgery
for hereditary MTC are increasingly based on the patient’s
specific RET oncogene codon mutation, which may be
determined with genetic testing.11–16
In our series, 12 of 22 (55%) patients receiving initial thy-
roid surgery for MTC had a familial MTC syndrome, such
Table 2. Therapeutic surgery group: patient and tumour characteristics
Operation n Age (yr) Female (%) Tumour size (cm)
Thyroidectomy Alone 9 39 ± 5 67 3.1 ± 0.6
Thyroidectomy + CLND 3 54 ± 17 33 4.3 ± 1.7
p NS NS
CLND = central lymph node dissection; NS = not significant.
Table 3. Therapeutic surgery for MTC: recurrence, re-operation and cure rates
Operation n Residual or recurrent MTC Re-operations Cures
Thyroidectomy Alone 9 8 (89%) 7 (78%) 1 (11%)
Thyroidectomy + CLND 3 0 0 3 (100%)
p 0.018 0.045 0.018
MTC = medullary thyroid carcinoma; CLND = central lymph node dissection.
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Figure. Kaplan–Meier disease-free survival curves for patients
with medullary thyroid carcinoma treated with thyroidectomy
alone (dotted line) and thyroidectomy plus central lymph node
dissection (solid line).
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as multiple endocrine neoplasia (MEN) Type 2. Ten of these
patients with familial MTC had no signs or symptoms of
carcinoma, and received prophylactic operations; the other
two patients had therapeutic surgery for thyroid nodules
preoperatively diagnosed as MTC. In all cases, the prophy-
lactic surgical procedure was thyroidectomy alone, without
neck dissection. Two patients in the prophylactic surgery
group were found to have small MTC tumours upon his-
tological examination of their resected thyroid specimens.
No patient in the prophylactic surgery group had residual
or recurrent MTC, and no patient required re-operation.
The optimal surgical management strategy for the
patient with a thyroid nodule diagnosed as MTC has 
been a subject of controversy. Historically, many general
surgeons—motivated, perhaps, by a desire to avoid serious
operative complications such as recurrent laryngeal nerve
injury and permanent hypoparathyroidism in treating 
a cancer with relatively low mortality—performed thy-
roidectomy alone, without systematic cervical node dis-
section. This is perhaps the reason why so many of the
patients in our series had thyroidectomy alone. These
operations were performed earlier in the study time period,
before the establishment of a section of endocrine surgery
within our department.
Retrospective studies have demonstrated that the
majority of patients with MTC have metastasis to local
lymph nodes at the time of diagnosis. In these studies,
patients treated with thyroidectomy alone frequently had
persistently elevated postoperative serum calcitonin lev-
els, and also had high rates of recurrence in the cervical
lymph nodes, necessitating re-operation. These data have
provided the rationale for surgeons to perform systematic
cervical lymphadenectomy at the time of initial thyroidec-
tomy for MTC, and this approach is emerging as the stan-
dard of care.17–26 Despite these data on the benefits of
cervical lymph node dissection for MTC, a significant
proportion of patients continue to receive less than optimal
initial surgical treatment. A recent review of the National
Cancer Institute’s Surveillance, Epidemiology and End
Results (SEER) database revealed that, for the 1994–2000
time period, 15% of patients with MTC in the national
database had less than total or near total thyroidectomy,
and 41% had no cervical lymph node dissection.27
Our series included 12 patients who received initial
surgery for a thyroid nodule preoperatively diagnosed as
MTC. Nine patients had thyroidectomy alone (Thyroidec-
tomy Alone Group), and three had thyroidectomy plus
CLND (CLND Group). Despite the more extensive resec-
tion, there was no increase in perioperative morbidity in
the CLND Group. However, compared to the Thyroid-
ectomy Alone Group, the CLND Group had significantly
lower rates of MTC recurrences and re-operations. The
cure rate for the CLND Group was 100%, versus only 11%
in the Thyroidectomy Alone Group, with cure defined as
the absence of any clinical, radiographic or biochemical
evidence of MTC at the time of last follow-up.
While the current study is limited by its retrospective
design, small sample size, and lack of standardized opera-
tive protocol, our findings are consistent with those of
numerous other retrospective and prospective studies
which have shown decreased MTC recurrence rates asso-
ciated with systematic lymphadenectomy at the time of
initial thyroidectomy.17,18,28,29 A more extensive initial
resection may reduce the need for re-operations. Reoper-
ative thyroid surgery has been associated with increased
rates of complications such as haemorrhage, perma-
nent hypoparathyroidism and recurrent laryngeal nerve
injury.30–33
Summarizing our series, thyroidectomy alone was an
effective prophylactic therapy for patients with hereditary
MTC, as no patient had residual disease or required 
re-operation. Furthermore, lymphadenectomy did not
increase morbidity in patients receiving initial surgery for
a MTC thyroid nodule. Finally, CLND, done at the time
of the initial operation, increased cure rates by decreasing
residual or recurrent disease and the need for additional
procedures. Therefore, we conclude that thyroidectomy
plus CLND is superior to thyroidectomy alone as an ini-
tial operation for patients with a thyroid nodule diag-
nosed as MTC. Given that results from our institution
and the SEER database27 indicate that a significant number
of patients with sporadic MTC are not treated with appro-
priate lymphadenectomy, increasing surgeon awareness is
required.
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